GSK to mark launching ceremony of adefovir dipivoxil for treatment of chronic hepatitis B

Published: 2004-02-10 06:58:00

Updated: 2004-02-10 06:58:00

GSK announced recently that following the launching of Zeffix (lamivudine), it will hold an international launching symposium for adefovir dipivoxil in February 14. The drug is a nucleotide analogue that demonstrated clinically significant antiviral activity in patients with chronic hepatitis B i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK